6 Stocks To Watch As The World Health Organization Declares Monkeypox Outbreak A Global Emergency
The World Health Organization (WHO) on Saturday declared the monkeypox outbreak a global emergency, its highest level of alert.
WHO Director-General Tedros Adhanom Ghebreyesus said more than 16,000 cases in more than 75 countries have now been reported around the world.
Recap Of Friday’s Biotech Catalysts – End Of The Day Summary
Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and…
VistaGen Says Data From Late-Stage Anxiety Study ‘Not Consistent’ With Prior Positive Phase 2 Study
VistaGen Therapeutics Inc (NASDAQ:VTGN) has announced topline results from its PALISADE-1 Phase 3 trial of PH94B for the acute treatment of…
iRhythm Gains FDA Clearance For Its Clinically Integrated ZEUS System
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced it received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization
AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference Jul. 31-Aug. 4
New data from the API ADAD Study to be presented in AAIC Focused Topic Session
New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer's
Bavarian Nordic’s Monkeypox Vaccine Gets Thumbs Up From EU Regulator
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a “positive opinion” recommending Bavarian Nordic…
Once A Cancer Company Silverback Merges With Small Biotech Working On Allergy Treatment
ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ:SBTX) in an all-stock transaction, with a new entity operating under the…
Liminal BioSciences Pulls Plug On Its Lead Development Program
Liminal BioSciences Inc (NASDAQ:LMNL) will discontinue the development of fezagepras based on results from the Phase 1a single ascending dose (SAD)…
ClearPoint Neuro Congratulates Partner PTC Therapeutics On Being Granted Marketing Authorization By The European Commission For Upstaza – First Disease-Modifying Treatment For AADC Deficiency
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted